Global Fusion Proteins Market is Segmented By Product (Immunoglobulin (Ig) fusion protein, Parathyroid hormone (PTH) fusion protein, Recombinant fusion protein, Other ), By Application (Biotechnology, Pharmaceutical, Others), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) â Share, Size, Outlook, and Opportunity Analysis, 2024-2031
Market Overview
The Global "Fusion Proteins Market" is estimated to reach at a CAGR of 10.5% during the forecast period (2024-2031).
A fusion protein contains at least two domains encoded by separate genes that have been linked so that these proteins are transcribed and translated as a single unit, yielding a single polypeptide.
Market Dynamics
The global fusion proteins market is expected to grow with increasing applications of fusion proteins.
The increasing applications of fusion proteins are expected to drive the market growth in the forecast period
The increasing application of fusion proteins for pulmonary arterial hypertension is expected to boost market growth. For instance, pulmonary arterial hypertension is a type of pulmonary hypertension caused by the thickening and narrowing of the tiny arteries in your lung. This narrowing restricts blood flow through the lungs, raising blood pressure in the lungs. Currently, vasodilators widen lung blood vessels and increase blood flow in patients with PAH. The researchers discovered that the fusion protein was more effective than vasodilators in treating PAH and preventing blood vessel remodeling by restoring a more normal balance of proliferation and cell death in the cells that make up blood vessel walls. For instance, when mice models were treated in the later stages of severe disease, the treatment increased the number of open lung vessels despite previous damage, in contrast to vasodilators, which did not. A wide range of fusion proteins have been studied in clinical trials, and several products are now available on the market. For instance, Amgen's Enbrel (etanercept) is used to treat moderate to severe plaque psoriasis, rheumatoid arthritis, and other diseases. A tumor necrosis factor receptor (TNFR) and an immunoglobulin (Ig) G1 Fc segment make up this TNF blocker. The TNFR provides specificity, while the Fc segment improves stability.
The limitations associated with fusion proteins is expected to hamper the market growth
Fusion proteins are engineered proteins that contain domains from multiple proteins and immunoglobulin. Combining different proteins in one molecule can cause instability, posing upstream and downstream manufacturing challenges. These problems are being developed in academia and the pharmaceutical industry by equipment vendors and drug companies.
Hence, the problems associated with developing fusion proteins for manufacturing purposes are expected to hamper the market growth.
COVID-19 Impact Analysis
The research using fused proteins to fight against COVID-19 is expected to have increased its market growth. For instance, SARS-CoV-2 uses angiotensin-converting enzyme 2 (ACE2) as a cell entry receptor to enter the host cell. According to studies, transiently produced human ACE2 fused with the Fc region of human IgG1 in Nicotiana benthamiana and tested the ACE2-Fc fusion protein's in vitro neutralisation efficacy. On day 6 post-infiltration, the recombinant ACE2-Fc fusion protein was expressed at 100 g/g leaf fresh weight in N. benthamiana. The recombinant fusion protein binds strongly to the SARS-CoV-2 receptor-binding domain (RBD). In addition, the plant-produced fusion protein demonstrated potent anti-SARS-CoV-2 activity in vitro. With an IC50 value of 0.84 g/ml, treatment with ACE2-Fc fusion protein after viral infection significantly inhibits SARS-CoV-2 infectivity in Vero cells.
Segment Analysis
Based on application biotechnology segment is expected to dominate the market growth
Biotechnology tools can create molecules that contain genes or portions of genes for two proteins. The resulting fusion protein may have several properties that improve its ability to treat disease. Several fusion proteins, for instance, have been created by fusing the binding domain of a cell surface receptor with the tail (Fc) portion of an antibody. The receptor portion serves as a decoy binding site, attracting and trapping molecules that otherwise contribute to disease. The antibody component allows the fusion protein to remain in the body for much longer than a circulating receptor would.
For instance, Etanercept is a soluble tumour necrosis factor-alpha (TNF) receptor fusion protein recombinant in humans. It is a large molecule with a molecular weight of 150 kDa that binds to TNF and reduces its role in autoimmune diseases such as ankylosing spondylitis, juvenile rheumatoid arthritis, psoriasis, psoriatic arthritis, rheumatoid arthritis, and, potentially, a variety of other disorders mediated by excess TNF. Etanercept is the most successful Fc-fusion protein, having outperformed the most successful therapeutic antibody, Bevacizumab. Etanercept was developed by researchers at Immunex, a biotechnology company later acquired by Amgen.
Market Geographical Share
North America region is expected to hold the largest market share in the global fusion proteins market
The increasing research and developments are expected to drive the market in this region. For instance, a company based in the United States, Novus Biologicals, LLC, develops and markets novel lifescience products. Novus Biologicals is also organised to provide a mechanism for commercialising unique biological materials to the biological research community. The company contributes significantly to the advancement of biological research by making these products widely available to institutional and commercial researchers. They manufacture fused protein products such as mCherry Antibody,mCherry Antibody (1C51), Luciferase Antibody, and others in different applications.
Hence, increasing companies in this region into the fused proteins market is expected to drive the market growth.
Competitive Landscape
The global fusion protein market is slightly competitive with mergers, collaborations and launches. Some key players are Abnova Corporation, Novus Biologicals, OriGene Technologies, Inc., Thermo Fisher Scientific Inc., PeproTech, Inc., ProSpec-Tany TechnoGene Ltd, F. Hoffmann-La Roche Ltd, Absolute Antibody., Amgen Inc, Sanofi S.A.
Sanofi S.A.
Overview: Sanofi S.A. is a multinational French healthcare corporation headquartered in Paris, France. By prescription sales, it is the world's fifth-largest pharmaceutical company. The company operates manufacturing sites in 32 countries and 21 research & development sites.
Product Portfolio: The company manufactures ELOCTATE [Antihemophilic Factor (Recombinant), Fc Fusion Protein] is an injectable medication used to help control and prevent bleeding in people who have Hemophilia A. (congenital Factor VIII deficiency).
Why Purchase the Report?
- Visualize the composition of the global fusion proteins market segmentation by product and application, highlighting the key commercial assets and players.
- Identify commercial opportunities in the global fusion proteins market by analyzing trends and co-development deals.
- Excel data sheet with thousands of data points of global fusion proteins market-level 4/5 segmentation.
- PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.
- Product mapping in excel for the key product of all major market players
The global fusion proteins market report would provide access to an approx. 45+market data table, 40+ figures, and 180 pages.
Target Audience
- Service Providers/ Buyers
- Industry Investors/Investment Bankers
- Education & Research Institutes
- Research Professionals
- Emerging Companies
- Manufacturers
Market Segmentation
Global Fusion Proteins Market - By Product
- Immunoglobulin (Ig) fusion protein
- Parathyroid hormone (PTH) fusion protein
- Recombinant fusion protein
- Other
Global Fusion Proteins Market - By Application
- Biotechnology
- Pharmaceutical
- Others
Global Fusion Proteins Market - By Region
- North America
- Europe
- South America
- Asia Pacific
- Middle East and Africa